Waterloo, Iowa Clinical Trials

A listing of Waterloo, Iowa clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy Surgery and/or Radiation Therapy

This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It …

MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 6396 views
  • 20 Nov, 2020
  • +1534 other locations
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)

pao2
pao2/fio2 ratio
SARS
coronavirus infection
covid-19
Northeast Iowa Medical Education Foundation
 (2.7 away) Contact site
  • 32 views
  • 08 Oct, 2020
  • +11 other locations
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and teeth. Drugs used in chemotherapy, …

platelet count
neutrophil count
rifampin
open biopsy
solid tumors
MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 65 views
  • 20 Nov, 2020
  • +887 other locations
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

myocardial infarction
infarct
arterial disease
diabetes
percutaneous coronary intervention
8400904 - Northeast Iowa Medical Education Foundation
 (1.5 away) Contact site
  • 1118 views
  • 25 Nov, 2020
  • +3405 other locations
S0820 Adenoma and Second Primary Prevention Trial

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

adenoma
aspirin
rectal carcinoma
unstable angina
anticoagulants
MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 2518 views
  • 24 Nov, 2020
  • +1023 other locations
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

This randomized phase III trial studies how well olanzapine with or without fosaprepitant work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in combination with …

treatment regimen
bilateral oophorectomy
diabetes
dexamethasone
metastasis
MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 109 views
  • 22 Nov, 2020
  • +563 other locations
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. …

neutrophil count
systemic chemotherapy
corticosteroid replacement therapy
ROS1
cardiac disease
MercyOne Waterloo Medical Center
 (2.7 away) Contact site
  • 206 views
  • 25 Nov, 2020
  • +777 other locations
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual …

MercyOne Waterloo Medical Center
 (2.7 away) Contact site
  • 139 views
  • 25 Nov, 2020
  • +468 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary …

epidermal growth factor receptor
inflammatory breast cancer
epirubicin
core needle biopsy
paclitaxel
MercyOne Waterloo Cancer Center ( Site 0016)
 (1.5 away) Contact site
  • 188 views
  • 25 Nov, 2020
  • +271 other locations
Dissemination of the Cardiovascular Risk Service

The objective of this study is to evaluate the implementation of of a remote, pharmacist-led cardiovascular risk service (CVRS) in 12 large, organizationally and culturally diverse hospitals and health-systems, many with high proportions of minority and underserved patients.

hypertension
systolic blood pressure
diabetes
Northeast Iowa Family Practice Center
 (1.5 away) Contact site
  • 67 views
  • 11 Oct, 2020
  • +13 other locations